Brain Advance Access published online on February 16, 2005
Brain, doi:10.1093/brain/awh445
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
1 CNRS-CEA URA2210, Service Hospitalier Frédéric Joliot, CHU Henri Mondor et Faculté de Médecine Paris 12, France; Faculty of Medicine, Hammersmith Hospital, Imperial College-MRC Clinical Sciences Centre and Division of Neuroscience, London, UK
* To whom correspondence should be addressed. Summary The reason for the high frequency of depression and anxiety in Parkinson's disease is poorly understood. Degeneration of neurotransmitter systems other than dopamine might play a specific role in the occurrence of these affective disorders. We used [11C]RTI-32 PET, an in vivo marker of both dopamine and noradrenaline transporter binding, to localize differences between depressed and non-depressed patients. We studied eight and 12 Parkinson's disease patients with and without a history of depression matched for age, disease duration and doses of antiparkinsonian medication. The depressed Parkinson's disease cohort had lower [11C]RTI-32 binding than non-depressed Parkinson's disease cases in the locus coeruleus and in several regions of the limbic system including the anterior cingulate cortex, the thalamus, the amygdala and the ventral striatum. Exploratory analyses revealed that the severity of anxiety in the Parkinson's disease patients was inversely correlated with the [11C]RTI-32 binding in most of these regions and apathy was inversely correlated with [11C]RTI-32 binding in the ventral striatum. These results suggest that depression and anxiety in Parkinson's disease might be associated with a specific loss of dopamine and noradrenaline innervation in the limbic system.
Received November 4, 2004
Revised January 13, 2005
Accepted January 18, 2005
Article
Depression in Parkinson's disease: loss of dopamine and noradrenaline innervation in the limbic system
2 Faculty of Medicine, Hammersmith Hospital, Imperial College-MRC Clinical Sciences Centre and Division of Neuroscience, London, UK
3 Institute of Neurology, Queen Square, London, UK
Philippe Remy, E-mail: remy{at}shfj.cea.fr
Abstract 
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  V. Voon, P. Krack, A. E. Lang, A. M. Lozano, K. Dujardin, M. Schupbach, S. Thobois, F. Tamma, J. Herzog, J. Samanta, et al. Reply: Parkinson's disease, DBS and suicide: a role for serotonin? Brain, October 1, 2009; 132(10): e127 - e127. [Full Text] [PDF]
|
|
|
|
 |
|
 P. M. Meyer, K. Strecker, K. Kendziorra, G. Becker, S. Hesse, D. Woelpl, A. Hensel, M. Patt, D. Sorger, F. Wegner, et al. Reduced {alpha}4{beta}2*-Nicotinic Acetylcholine Receptor Binding and Its Relationship to Mild Cognitive and Depressive Symptoms in Parkinson Disease Arch Gen Psychiatry, August 1, 2009; 66(8): 866 - 877. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Worbe, N. Baup, D. Grabli, M. Chaigneau, S. Mounayar, K. McCairn, J. Feger, and L. Tremblay Behavioral and Movement Disorders Induced by Local Inhibitory Dysfunction in Primate Striatum Cereb Cortex, August 1, 2009; 19(8): 1844 - 1856. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. N. Taylor, W. M. Caudle, K. R. Shepherd, A. Noorian, C. R. Jackson, P. M. Iuvone, D. Weinshenker, J. G. Greene, and G. W. Miller Nonmotor Symptoms of Parkinson's Disease Revealed in an Animal Model with Reduced Monoamine Storage Capacity J. Neurosci., June 24, 2009; 29(25): 8103 - 8113. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. W. Olanow, M. B. Stern, and K. Sethi The scientific and clinical basis for the treatment of Parkinson disease (2009) Neurology, May 26, 2009; 72(21_Supplement_4): S1 - S136. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Menza, R. D. Dobkin, H. Marin, M. H. Mark, M. Gara, S. Buyske, K. Bienfait, and A. Dicke A controlled trial of antidepressants in patients with Parkinson disease and depression Neurology, March 10, 2009; 72(10): 886 - 892. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Reeves, R. Brown, R. Howard, and P. Grasby Increased striatal dopamine (D2/D3) receptor availability and delusions in Alzheimer disease Neurology, February 10, 2009; 72(6): 528 - 534. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S.-Y. Lim, S. H. Fox, and A. E. Lang Overview of the Extranigral Aspects of Parkinson Disease Arch Neurol, February 1, 2009; 66(2): 167 - 172. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Nandhagopal, M. J. McKeown, and A. J. Stoessl Invited Article: Functional imaging in Parkinson disease Neurology, April 15, 2008; 70(16_Part_2): 1478 - 1488. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
U. Walter, J. Hoeppner, L. Prudente-Morrissey, S. Horowski, S. C. Herpertz, and R. Benecke Parkinson's disease-like midbrain sonography abnormalities are frequent in depressive disorders Brain, July 1, 2007; 130(7): 1799 - 1807. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N I Bohnen, D I Kaufer, R Hendrickson, G M Constantine, C A Mathis, and R Y Moore Cortical cholinergic denervation is associated with depressive symptoms in Parkinson's disease and parkinsonian dementia J. Neurol. Neurosurg. Psychiatry, June 1, 2007; 78(6): 641 - 643. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. B. Lohr and M. P. Caligiuri Abnormalities in Motor Physiology in Bipolar Disorder J Neuropsychiatry Clin Neurosci, August 1, 2006; 18(3): 342 - 349. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Suzuki, T. Hoshino, K. Shigemasu, and M. Kawamura Disgust-specific impairment of facial expression recognition in Parkinson's disease Brain, March 1, 2006; 129(3): 707 - 717. [Abstract] [Full Text] [PDF]
|
|